enGene Therapeutics Will Host Bladder Cancer Webinar
The company will present clinical trial data and case studies on October 15, 2026.
Updated on Oct. 13, 2026 in Cancer
Live Poll
Do you trust that new medical treatments are safe when based primarily on preclinical data?
enGene Therapeutics will host a webinar on October 15, 2026, to discuss its ongoing research in genetic medicine. Two medical experts will present clinical data and case studies related to the treatment of bladder cancer.
Why it matters
The presentation aims to explain the scientific rationale behind incorporating a surfactant bladder rinse into the LEGEND clinical trial. This approach is intended to improve the efficacy of gene therapies, building on results observed in preclinical models.
The LEGEND trial protocol includes a polidocanol surfactant rinse prior to the administration of detalimogene voraplasmid in patients with BCG-unresponsive bladder cancer. Clinical data is currently being collected through an additional patient cohort.
The players
enGene Therapeutics
The company is a clinical-stage organization that develops genetic medicines.
David J. Cahn
He is a medical doctor practicing at Colorado Urology.
Suzanne B. Merrill
She is a medical doctor practicing at Colorado Urology.
The details
The webinar will focus on how the surfactant rinse, used before the intravesical delivery of detalimogene, impacts treatment outcomes. Dr. David J. Cahn and Dr. Suzanne B. Merrill from Colorado Urology are slated to present their findings and experiences regarding this method.
Timeline
October 15, 2026, at 10:00 AM ET is when the company will host the webinar.
The Big Picture
The upcoming webinar provides a progress update on the data collection and methodology currently being utilized in the LEGEND trial. This presentation follows the ongoing development of gene therapies designed to enhance cellular uptake in targeted bladder tissues.
This research focuses on potential new treatment options for patients with high-risk, BCG-unresponsive bladder cancer. The webinar results may offer insight into how refined delivery protocols could eventually alter clinical treatment standards for this patient population.
The takeaway
The use of surfactants in gene therapy represents a targeted effort to improve treatment outcomes for complex conditions like bladder cancer. Stakeholders monitoring this field should observe how preclinical data translates into clinical results as the trial progresses.
Further reading
Learn more about the latest research in this field at the Cancer section.
Live Poll
Do you trust that new medical treatments are safe when based primarily on preclinical data?
